-
1
-
-
0041629528
-
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
-
Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
-
(2003)
J Clin Oncol
, vol.21
, Issue.14
, pp. 2636-2644
-
-
Vogelzang, N.J.1
Rusthoven, J.J.2
Symanowski, J.3
Denham, C.4
Kaukel, E.5
Ruffie, P.6
-
2
-
-
57649088756
-
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
-
Stebbing J., Powles T., McPherson K., Shamash J., Wells P., Sheaff M.T., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009, 63(1):94-97.
-
(2009)
Lung Cancer
, vol.63
, Issue.1
, pp. 94-97
-
-
Stebbing, J.1
Powles, T.2
McPherson, K.3
Shamash, J.4
Wells, P.5
Sheaff, M.T.6
-
3
-
-
43449092540
-
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
-
Muers M.F., Stephens R.J., Fisher P., Darlison L., Higgs C.M., Lowry E., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371(9625):1685-1694.
-
(2008)
Lancet
, vol.371
, Issue.9625
, pp. 1685-1694
-
-
Muers, M.F.1
Stephens, R.J.2
Fisher, P.3
Darlison, L.4
Higgs, C.M.5
Lowry, E.6
-
4
-
-
84901932964
-
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
-
[Epub ahead of print]
-
Zucali P.A., Perrino M., Lorenzi E., Ceresoli G.L., De Vincenzo F., Simonelli M., et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2013, [Epub ahead of print]. 10.1016/j.lungcan.2013.11.011.
-
(2013)
Lung Cancer
-
-
Zucali, P.A.1
Perrino, M.2
Lorenzi, E.3
Ceresoli, G.L.4
De Vincenzo, F.5
Simonelli, M.6
-
5
-
-
0033564135
-
A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
-
van Meerbeeck J.P., Baas P., Debruyne C., Groen H.J., Manegold C., Ardizzoni A., et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999, 85(12):2577-2582.
-
(1999)
Cancer
, vol.85
, Issue.12
, pp. 2577-2582
-
-
van Meerbeeck, J.P.1
Baas, P.2
Debruyne, C.3
Groen, H.J.4
Manegold, C.5
Ardizzoni, A.6
-
6
-
-
21344471421
-
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
-
Manegold C., Symanowski J., Gatzemeier U., Reck M., von Pawel J., Kortsik C., et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005, 16(6):923-927.
-
(2005)
Ann Oncol
, vol.16
, Issue.6
, pp. 923-927
-
-
Manegold, C.1
Symanowski, J.2
Gatzemeier, U.3
Reck, M.4
von Pawel, J.5
Kortsik, C.6
-
7
-
-
0035141576
-
Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B
-
Kindler H.L., Millard F., Herndon J.E., Vogelzang N.J., Suzuki Y., Green M.R. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31(2-3):311-317.
-
(2001)
Lung Cancer
, vol.31
, Issue.2-3
, pp. 311-317
-
-
Kindler, H.L.1
Millard, F.2
Herndon, J.E.3
Vogelzang, N.J.4
Suzuki, Y.5
Green, M.R.6
-
8
-
-
0037183683
-
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
-
Nowak A.K., Byrne M.J., Williamson R., Ryan G., Segal A., Fielding D., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002, 87(5):491-496.
-
(2002)
Br J Cancer
, vol.87
, Issue.5
, pp. 491-496
-
-
Nowak, A.K.1
Byrne, M.J.2
Williamson, R.3
Ryan, G.4
Segal, A.5
Fielding, D.6
-
9
-
-
18244404869
-
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
-
van Haarst J.M., Baas P., Manegold C., Schouwink J.H., Burgers J.A., de Bruin H.G., et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002, 86(3):342-345.
-
(2002)
Br J Cancer
, vol.86
, Issue.3
, pp. 342-345
-
-
van Haarst, J.M.1
Baas, P.2
Manegold, C.3
Schouwink, J.H.4
Burgers, J.A.5
de Bruin, H.G.6
-
10
-
-
0032895398
-
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study
-
Byrne M.J., Davidson J.A., Musk A.W., Dewar J., van Hazel G., Buck M., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17(1):25-30.
-
(1999)
J Clin Oncol
, vol.17
, Issue.1
, pp. 25-30
-
-
Byrne, M.J.1
Davidson, J.A.2
Musk, A.W.3
Dewar, J.4
van Hazel, G.5
Buck, M.6
-
11
-
-
41149175598
-
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
-
Zucali P.A., Ceresoli G.L., Garassino I., De Vincenzo F., Cavina R., Campagnoli E., et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008, 112(7):1555-1561.
-
(2008)
Cancer
, vol.112
, Issue.7
, pp. 1555-1561
-
-
Zucali, P.A.1
Ceresoli, G.L.2
Garassino, I.3
De Vincenzo, F.4
Cavina, R.5
Campagnoli, E.6
-
12
-
-
1342267614
-
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
-
Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15(2):257-260.
-
(2004)
Ann Oncol
, vol.15
, Issue.2
, pp. 257-260
-
-
Byrne, M.J.1
Nowak, A.K.2
-
13
-
-
84858403099
-
VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial
-
Krug L.M., Kindler H., Calvert C., Manegold C., Tsao A.S., Fennell D., et al. VANTAGE 014: vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer 2011, 47(2):2-3.
-
(2011)
Eur J Cancer
, vol.47
, Issue.2
, pp. 2-3
-
-
Krug, L.M.1
Kindler, H.2
Calvert, C.3
Manegold, C.4
Tsao, A.S.5
Fennell, D.6
-
14
-
-
84860674283
-
BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma
-
Busacca S., Sheaff M., Arthur K., Gray S.G., O'Byrne K.J., Richard D.J., et al. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol 2012, 227(2):200-208.
-
(2012)
J Pathol
, vol.227
, Issue.2
, pp. 200-208
-
-
Busacca, S.1
Sheaff, M.2
Arthur, K.3
Gray, S.G.4
O'Byrne, K.J.5
Richard, D.J.6
|